We are independent & ad-supported. We may earn a commission for purchases made through our links.

Advertiser Disclosure

Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.

How We Make Money

We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently from our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What is Atripla®?

By T. Broderick
Updated May 17, 2024
Our promise to you
WiseGeek is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At WiseGeek, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Atripla® is an oral, once-a-day medication used to treat HIV. Developed as a cooperation between Gilead Sciences and Bristol-Myers Squibb, the drug combines three separate HIV medications. Approved by the American Food and Drug Administration in 2006, this combination medication greatly simplifies a patient's treatment schedule. Like many HIV anti-retroviral medications, Atripla® is very expensive. Side effects of the medication are generally mild but can become serious if a patient has hepatitis along with HIV.

A single dose of Atripla® combines three anti-retroviral medications previously used to treat HIV: efavirenz, tenofovir and emtricitabine. Efavirenz, developed in 1998, is prescribed both to treat HIV and prevent its transmission to individuals recently exposed to the virus from needles or unprotected sex. Tenofovir blocks an enzyme needed by HIV to reproduce. Emtricitabine is like tenofovir as it impedes HIV's ability to replicate. Combined, these three medications create a powerful tool in suppressing the virus in the human body.

Atripla® is the first daily dose mediation approved in the United States to treat HIV. Before its approval, patients faced strict medication schedules that involved different medications throughout the day. Taking different medications also meant more side effects and drug interactions for patients. Atripla® and similar medications approved after 2006 greatly simplify the process of managing HIV. This convenience, though, is extremely expensive.

Atripla® is patented and co-owned by Gilead Sciences and Bristol-Myers Squibb. As of January 2011, a one month's supply of the medication in the United States is $1,850 US Dollars (USD). International licensing agreements have made the medication less expensive in countries such as India. Even where the medication is cheaper, though, the cost per unit is still out of reach for many HIV positive individuals.

Though a benefit of Atripla® is the reduced number of side effects when compared to a traditional cocktail of HIV medication, serious complications can still occur. Headaches and upset stomach are the most reported side effect. Others experience mood swings, depression and mild hallucinations. In rare cases, individuals experience liver damage; it is most likely when patients are co-infected with hepatitis. A physician may prescribe a different set of anti-retrovirals if these latter symptoms begin to manifest.

Certain medications may cause dangerous drug interactions with Atripla®. These medications include prescription antihistamines and anti-seizure drugs. Before beginning any new medication to treat HIV, fully disclosing the medications one is taking to a physician greatly reduces the chances of drug interaction.

WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.

Discussion Comments

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.